Últimas noticias sobre AbbVie (NYSE:ABBV) Bolsa

ABBVIE INC

AbbVie

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

Interest,Rate,And,Dividend,Concept,,Personal,Investment,,,Return,On

Personal Finance

ABBV

AVGO

HTGC

SCHD

Las 10 mejores participaciones en dividendos de un jubilado de Reddit, que vive cómodamente de los pagos de dividendos.

Jubilado comparte sus 10 principales participaciones en dividendos para una jubilación cómoda

CHWY

RIVN

ULTA

Descubre las acciones con mayor potencial en 2025 en belleza, salud y tecnología. ¿Qué estrategias impulsan su éxito?

Wall Street revela 4 acciones prometedoras: Sectores clave para invertir en 2025

AbbVie Inc

President Donald Trump on Wednesday announced a slew of tougher-than-anticipated tariffs, but there are some <a href="https://www.whitehouse.gov/fact-sheets/2025/03/fact-sheet-president-donald-j-trump-addresses-the-threat-to-national-security-from-imports-of-timber-lumber-and-their-derivative-products/">notable exemptions</a> to the steep levies.&nbsp;
Here's a look at which products and sectors are excluded <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44626421/trumps-reign-of-tariffs-unleashes-d-day-on-wall-street-analyst-warns-of-stagflation-risk">from the reciprocal tariffs:&nbsp;</a>
Semiconductors: Semiconductors were exempted from the sweeping new tariffs due to their critical role in many technologies. However, the sector was deep in the red in Thursday's trading with shares of Broadcom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) down 6.78% and ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) down 3.69%.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44628368/trumps-tariffs-prompt-china-to-vow-countermeasures-experts-see-retaliation-likely">Trump&#8217;s Tariffs Prompt China To Vow &#8216;Countermeasures&#8217;: Experts See Retaliation Likely&nbsp;</a>
Pharmaceuticals: Trump excluded pharmaceuticals from the new tariffs, likely a relief for the industry that had been under pressure following the president's prior comments suggesting a 25% tariff on pharmaceutical imports.&nbsp;
"The United States can no longer produce enough antibiotics to treat our sick," Trump said Wednesday. "We have a tremendous problem, we have to go to foreign countries to treat our sick. If anything ever happened from a war standpoint, we wouldn't be able to do it."
Pharmaceutical stocks are defying Thursday's broad market drop with shares of AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) both in the green in mid-morning trading. 
Lumber: Lumber is another product excluded from Trump's tariff plan, for now. The administration said it is investigating how reliance on imported lumber impacts national security and economic stability. Exemptions have been granted to avoid immediate disruptions in supply chains critical to construction and defense in the meantime.&nbsp;
Gold, Copper: Certain metals and minerals including copper, gold and others not found in the U.S. were also exempted from the reciprocal tariff plan.&nbsp;
Gold dropped more than 3%, falling below $3,060 per ounce on Thursday after touching a new record high above $3,160. The SPDR Gold Trust ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), tracking the price of gold, was down only slightly, bucking the broader market declines.&nbsp;
Energy: Oil, gas and refined products imports were exempted from the sweeping new reciprocal tariffs, the White House said on Wednesday.&nbsp;
Shares of the United States Oil Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) fell 7.8% on Thursday, however, as the sweeping tariff plan could threaten global demand.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44537429/cathie-wood-doubles-down-on-2600-tesla-stock-price-prediction">Cathie Wood Doubles Down On $2,600 Tesla Stock Price Prediction</a></li>
</ul>
Photo: Shutterstock/Alones

Government

News

Specialty ETFs

Commodities

Politics

Global

Economics

Markets

Movers

Tech

ETFs

ASML

Trump's Tariff Exemptions Include Semiconductors, Pharmaceuticals, Oil And More

Investors with a lot of money to spend have taken a bearish stance on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABBV, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 16 uncommon options trades for AbbVie.
This isn't normal.
The overall sentiment of these big-money traders is split between 31% bullish and 50%, bearish.
Out of all of the special options we uncovered, 10 are puts, for a total amount of $786,285, and 6 are calls, for a total amount of $289,665.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $185.0 to $215.0 for AbbVie over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for AbbVie's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale activity within a strike price range from $185.0 to $215.0 in the last 30 days. 
<h3>AbbVie 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743533132_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/11/25</td>
<td>$2.61</td>
<td>$2.56</td>
<td>$2.56</td>
<td>$205.00</td>
<td>$151.8K</td>
<td>678</td>
<td>1.2K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/11/25</td>
<td>$2.7</td>
<td>$2.41</td>
<td>$2.7</td>
<td>$205.00</td>
<td>$113.9K</td>
<td>678</td>
<td>1.7K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$5.3</td>
<td>$5.15</td>
<td>$5.3</td>
<td>$200.00</td>
<td>$106.0K</td>
<td>4.8K</td>
<td>520</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/11/25</td>
<td>$2.51</td>
<td>$2.5</td>
<td>$2.5</td>
<td>$205.00</td>
<td>$99.2K</td>
<td>678</td>
<td>7</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$9.35</td>
<td>$9.15</td>
<td>$9.28</td>
<td>$210.00</td>
<td>$92.7K</td>
<td>7.7K</td>
<td>148</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>AbbVie's Current Market Status</h3>
<ul>
<li>With a trading volume of 3,955,651, the price of ABBV is up by 0.66%, reaching $210.91.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 24 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for AbbVie</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $231.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on AbbVie, which currently sits at a price target of $240. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Neutral rating for AbbVie, targeting a price of $223. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AbbVie, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Looking At AbbVie's Recent Unusual Options Activity

Deep-pocketed investors have adopted a bullish approach towards AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ABBV usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 23 extraordinary options activities for AbbVie. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 43% leaning bullish and 21% bearish. Among these notable options, 16 are puts, totaling $1,740,435, and 7 are calls, amounting to $359,373.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $180.0 to $220.0 for AbbVie over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of AbbVie stands at 3048.78, with a total volume reaching 10,547.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in AbbVie, situated within the strike price corridor from $180.0 to $220.0, throughout the last 30 days.
<h3>AbbVie 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743447675_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$8.3</td>
<td>$8.1</td>
<td>$8.2</td>
<td>$185.00</td>
<td>$410.0K</td>
<td>114</td>
<td>500</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$3.15</td>
<td>$3.0</td>
<td>$3.05</td>
<td>$195.00</td>
<td>$305.0K</td>
<td>2.7K</td>
<td>1.2K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$5.5</td>
<td>$5.3</td>
<td>$5.3</td>
<td>$200.00</td>
<td>$161.6K</td>
<td>4.1K</td>
<td>327</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$4.05</td>
<td>$3.9</td>
<td>$3.97</td>
<td>$205.00</td>
<td>$134.9K</td>
<td>694</td>
<td>1.2K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$3.25</td>
<td>$3.1</td>
<td>$3.1</td>
<td>$205.00</td>
<td>$91.4K</td>
<td>694</td>
<td>558</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
In light of the recent options history for AbbVie, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of AbbVie</h3>
<ul>
<li>Currently trading with a volume of 4,607,370, the ABBV's price is up by 1.79%, now at $208.96. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 25 days.</li>
</ul>
<h3>What The Experts Say On AbbVie</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $231.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on AbbVie with a target price of $240. 
&#x2A; An analyst from B of A Securities has decided to maintain their Neutral rating on AbbVie, which currently sits at a price target of $223. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AbbVie options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Decoding AbbVie's Options Activity: What's the Big Picture?

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/03/28/final-trades-paypal-meta-abbvie-and-snowflake.html">Halftime Report Final Trades</a>,&#8221; Malcolm Ethridge of CIC Wealth Management named PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) <a href="https://www.benzinga.com/25/02/43942860/paypal-eyes-double-digit-eps-growth-by-2027-teams-up-with-verifone-jp-morgan-more">his final trade</a>.
On Feb. 25, PayPal issued an outlook ahead of its Investor Day event. The company reiterated guidance for an adjusted EPS growth of 6%-10% and transaction margin dollar growth, excluding the impact of interest on customer balances of growth of at least 5%. The company expects high single-digit transaction margin dollar growth and low teens+ adjusted EPS growth by 2027.
Kevin Simpson of Capital Wealth Planning said Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) is his top pick out of the Mag 7 names, having great free cash flow and huge margins.
On Friday, Citizens Capital Markets analyst Andrew Boone reiterated Meta Platforms with a Market Outperform rating and maintained a $750 price target.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Jim Lebenthal of Cerity Partners said AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is a stock in a nice uptrend. It has pulled back a little bit. It has a very attractive valuation, good management and good product pipelines, he added.
AbbVie released on March 15 the final analysis of the confirmatory Phase 3 MIRASOL trial of Elahere (mirvetuximab soravtansine-gynx) in women with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) compared to chemotherapy.
Stephanie Link picked Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>), down 23% from its highs.
As per the recent news, Snowflake, on March 6, appointed Mike Gannon as chief revenue officer.
Price Action:
<ul>
<li>PayPal shares dipped 5.4% to close at $65.15 on Friday.</li>
<li>Meta shares fell 4.3% to close at $576.74 during Friday's session.</li>
<li>AbbVie shares gained 1.3% to close at $205.29 on Friday.</li>
<li>Snowflake shares dipped 4.1% to settle at $150.63.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44534977/jim-cramer-healthpeak-properties-is-a-reasonable-reit-recommends-buying-this-health-care-stock">Jim Cramer: Healthpeak Properties Is A &#8216;Reasonable&#8217; REIT, Recommends Buying This Health Care Stock</a></li>
</ul>
Photo: Shutterstock

Media

Trading Ideas

PYPL

SNOW

Meta, Snowflake, PayPal And Health Care Stock On CNBC's 'Final Trades'

Analyst Ratings

CNBC Halftime Report Final Trades: PayPal Holdings, Meta Platforms, AbbVie, Snowflake

<a href="https://in.benzinga.com/personal-finance/25/03/44376666/high-yield-dividend-investor-making-12900-per-year-names-10-favorite-stocks-took-me-almost-3-years-to-get-to-this-point">Dividend</a> investing has long been a favorite strategy for retirees and income-focused investors. Unlike growth-oriented assets, which depend on share price appreciation, dividend-paying stocks generate regular payouts.
But why do so many investors run to dividend stocks and ETFs? Dividends offer a way to compound wealth by reinvesting the generated income while also providing financial stability in <a href="https://in.benzinga.com/personal-finance/25/03/44476778/author-says-dave-ramsey-is-completely-ignorant-of-sequence-of-returns-risk-questions-whether-1-million-is-really-enough-for-retirement">retirement</a>. High-quality dividend companies also have a history of increasing payouts year after year, helping investors keep up with inflation.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
Still, total returns are also important in investing, as one investor demonstrated. The investor, a Reddit user who shared his journey in the r/Dividends community, is a 61-year-old retiree who spent 37 years building his portfolio on growth before switching to a dividend strategy when approaching retirement. He ultimately crafted a portfolio yielding around 8% and named his top holdings in the thread.
&#8220;My big break was being mostly cash in early 2020 because I felt the market had gotten too expensive. That was largely luck but it worked great. March 2020 was really fun. I spent between $1 million to $2 million on stocks in about 30 days and the resulting market rise after that secured my retirement. When I started learning about dividends, I included it as one option but still looked at it from a perspective of total returns,&#8221; he shared.
Now, he lives comfortably off dividends, rarely selling stocks for income, and relying on growing dividend payouts. The investor has shared his holdings in the Reddit community, so let&#8217;s see what they are.
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a>
<h2 class="wp-block-heading">Retiree Living Off Dividends Shares Top 10 Holdings in Reddit Investing Community</h2>
AbbVie
AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is a global biopharmaceutical company focusing on the research and development of advanced treatments for complex diseases. Investors love ABBV because of its strong product portfolio and its steady dividend history, paying approximately 3.23% annually in dividends.
Arbor Realty Trust
A real estate investment trust with a high yield, Arbor Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABR#NYSE">ABR</a>) focuses on originating and servicing loans for multifamily and commercial real estate. The company pays investors around 14.11% in dividends annually.
Broadcom
A tech dividend grower, Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) is known for semiconductors and software, and despite a modest yield, it raises payouts aggressively. AVGO has a 1.24% dividend yield per year.
Hercules Capital
Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) is a business development company that offers venture debt to technology and life sciences companies. Investors love HTGC since it offers high dividend yields and exposure to emerging growth companies. The company pays investors around 9.39% in dividends.
Mastercard
Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) is a well-known global technology company operating in the payments industry. MA pays investors approximately 0.56% in dividends yearly.
See Also: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Realty Income Corporation
A real estate investment trust, Realty Income Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) is known as &#8220;the monthly dividend company&#8221; since it pays investors every month. O owns over 6,500 properties under long-term lease agreements and has a very diversified property portfolio, paying 5.76% per year in dividends.
Target
Operating as a general merchandise retailer selling a wide assortment of products, such as household essentials, apparel, and electronics, Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) generates approximately 4.23% in dividends.
Vanguard Total Stock Market ETF
Vanguard Total Stock Market ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTI#NYSE">VTI</a>) tracks the performance of the CRSP US Total Market Index, covering virtually all investable U.S. stocks. With a dividend of around 1.35% per year, the ETF is loved by investors because it offers broad exposure to the U.S. equity market with low expense ratios.​
Schwab U.S. Dividend Equity ETF
Tracking the performance of the Dow Jones U.S. Dividend 100 Index, Schwab U.S. Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>) focuses on high-dividend-yielding U.S. stocks. SCHD generates around 3.81% in dividends.
Invesco S&amp;P SmallCap 600 Revenue ETF
Paying around 1.47% in dividends per year, Invesco S&amp;P SmallCap 600 Revenue ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RWJ#NYSE">RWJ</a>) tracks the performance of the S&amp;P SmallCap 600 Revenue-Weighted Index. Investors love RWJ because it provides exposure to small-cap U.S. companies weighted by earnings.
Read Next:
<ul>
<li>Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

Retired At 58, He 'Spent Between $1M-$2M On Stocks' – Investor Who Built An 8% Yield Portfolio And Lives Off Dividends Shares Top Holdings

No one stumbles upon <a href="https://www.benzinga.com/personal-finance/24/12/42301100/most-americans-dont-see-wealth-as-the-key-to-financial-success-heres-what-matters-more-to-59-of-them">financial success</a> by accident. Wealth is built through discipline, learning from mistakes, and sticking to an approach even when the market seems to go awry. Few investing strategies showcase this better than <a href="https://www.benzinga.com/personal-finance/25/03/44374276/reddit-explodes-over-dividend-math-how-much-would-the-annual-dividend-be-for-a-280k-investment-investors-debate-schds-future-growth">dividend</a> investing.
Dividend investing is the slow-and-steady journey of the financial world, paying consistently while also providing growth in the background, making it perfect for retirees, long-term investors, and anyone who wants passive income.
Don't Miss:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
Still, this approach can also be risky for some if they pick the wrong stocks. One military veteran and Reddit user recently shared his investing journey that started with him making costly mistakes to now earning him $10,000 in dividends per year.
With 13 years of investing experience, the poster, an enlisted service member, had to learn what works through trial and error. He says he tried to be smarter than the market early on, leading to him selling big winners too soon and holding onto losers for too long.
&#8220;I bought [General Electric] in my Roth at what I thought was a great price point of $14.50 or something. Had to [dollar-cost average] over several years to bring the cost basis down and missed out on having that money in better spots in the biggest bull market year I have been a part of,&#8221; he shared.
The 36-year-old mentioned that he&#8217;s gradually shifted his strategy to dividend shares now and his $296,570 portfolio already generates over $10,000 annually in dividends. Let&#8217;s see what dividend shares and ETFs the investor holds.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
<h2 class="wp-block-heading">From Fatal Mistakes to $10,000/Year in Dividend Income—Reddit Investor Shares Top 10 Stocks and ETFs in His Portfolio</h2>
Abbott Laboratories
Healthcare company, Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) specializes in medical devices, pharmaceuticals, and nutritional products. With a 1.89% dividend yield per year, ABT is known for its diversified product portfolio and steady payments.
AbbVie
Pharmaceutical giant AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) focuses on the research and development of therapies for various health conditions. Investors love ABBV because it has a strong yield, generating around 3.28% in dividends per year, and a stable pipeline of drugs.
ConocoPhillips
Energy giant ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) engages in the exploration and production of oil and natural gas. COP pays investors approximately 3.05% in annual dividends.
Duke Energy Corporation
Duke Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) is one of the largest electric power companies in the U.S. and is known for its stable revenue and consistent dividends. DUK generates around 3.62% in annual dividend yield.
Apple
Technology giant Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) has a modest dividend yield but a strong growth potential, and that&#8217;s why both growth and income-focused investors are attracted to this stock. APPL pays investors around 0.47% in dividends per year.
See Also: Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a>
Mastercard
Electronic payments company Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) benefits from the ongoing shift toward cashless transactions. This, and the growth potential it offers makes MA a go-to stock for many investors. The company generates around 0.56% in annual dividends.
Verizon
Telecom Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) provides wireless and wireline services. With a dividend yield of approximately 6.25% annually, VZ has a stable cash flow, making it a favorite among individual stock investors.
Altria Group
Tobacco giant Altria Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) is mainly known for the Marlboro brand. MO offers a high dividend yield of 7.21% per year, appealing to those seeking higher passive income.
Global X SuperDividend ETF
Tracking the performance of the Indxx SuperDividend U.S. Low Volatility Index, Global X SuperDividend ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIV#NYSE">DIV</a>) focuses on high dividend yields and is known to retain low volatility. DIV generates around 11.37% in dividend yield per year.
Invesco Preferred ETF
Invesco Preferred ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGX#NYSE">PGX</a>) invests mainly in preferred stocks, which are hybrid securities offering features of both stocks and bonds.​ Paying investors around 5.85% in annual dividends, PGX is a favorite for those who seek higher income.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>

AAPL

From Rookie Mistakes To $10K/Year In Dividends – Military Veteran Who 'Made A Few Great Plays' Shares His 10 Biggest Bets

REHOVOT, Israel, March 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced its 2024 financial results and provided a corporate update.
"This past year to date, we have progressed on all fronts - from advancing our collaborative programs, to gaining momentum on our proprietary programs as well as our marketed products.&nbsp; Specifically, we leveraged additional preclinical studies findings, refined a commercial design of our regenerative breast implants, gained an additional U.S. patent related to our photocurable dermal filler and also broadened the distribution network for our commercial product, Vergenix STR. On the aesthetic medicine front, following a development achievement we received a $2 million payment from our collaboration partner, AbbVie.&nbsp; In tandem with our progress, we have also been very careful to optimize our costs. Therefore, we expect that our cash position, that has been supported by both milestone payments and incremental sales revenue, will allow us to be selective and support a capitalized path in the interest of our shareholders", commented CollPlant's Chief Executive Officer, Yehiel Tal.

Biotech

General

CLGN

Collplant Announces Six-Month Study Data From Its Regenerative Breast Implant Program & That It Recently Received A $2M Development Payment From Abbvie

On Monday, Stifel initiated coverage on Avalo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>). Avalo&#8217;s lead asset is AVTX-009, an anti-IL-1β mAb <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">targeting inflammatory diseases</a>.
The company initiated a Phase 2 LOTUS trial, which will include approximately 180 adults with hidradenitis suppurativa (HS), to evaluate the efficacy and safety of subcutaneous bi-weekly and monthly dosing regimens compared to placebo. Topline data is <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44413131/avalo-reports-2024-financial-results-and-recent-business-updates" rel="noreferrer noopener">expected in 2026</a>.
Avalo continues to evaluate AVTX-009 for additional immune-mediated diseases with plans to <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38278240/avalo-therapeutics-newly-acquired-ex-eli-lilly-drug-could-stand-out-in-competitive-" rel="noreferrer noopener">announce a second indication</a>.
Analyst Alex Thompson writes that the following proof-of-concept data in HS from AbbVie Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) lebrikizumab, an IL-1α/β bispecific success for AVTX-009, is highly de-risked given the strong evidence suggesting that IL-1β blockade represents the key driver of efficacy for Lutikizumab.
In January 2024, AbbVie&#8217;s Phase 2 results showed that adults with moderate to severe hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy who received lutikizumab (ABT-981) 300 mg every other week or 300 mg weekly achieved higher response rates (59.5% nominal p=0.027 and 48.7%, nominal p=0.197, respectively) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/01/n36531984/lutikizumab-showed-positive-results-in-a-phase-2-trial-of-adults-with-moderate-to-severe-hidradeni" rel="noreferrer noopener">than placebo (35%)</a>.
Stifel writes that AVTX-009 can achieve comparable efficacy to lutikizumab albeit with the potential for superior dosing (Q4W vs. Q2W), equating to a meaningful minority share within the growing HS market yielding over $2 billion drug in the US alone amid significant strategic interest in the space.
Stifel has initiated with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/AVTX/analyst-ratings" rel="noreferrer noopener">price target of $36</a>.
&#8220;Bottomline we think AVTX represents an attractive HS pure-play with a favorable risk-reward heading into topline Ph2 data in the 2026 timeframe. Strong external HS newsflow over the next 12 months offers an additional tailwind,&#8221; Stifel analyst writes.
Cash and cash equivalents&nbsp;were $134.5 million as of December 31, 2024. The company&#8217;s current cash on hand is expected to fund operations into at least 2027.
Price Action: AVTX stock is up 15.5% at $8.81 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44473549/pony-ai-q4-revenue-slumps-nearly-30-as-robotaxi-sales-decline-loss-widens" target="_blank" rel="noreferrer noopener">Pony AI Q4: Revenue Slumps Nearly 30% As Robotaxi Sales Decline, Loss Widens</a></li>
</ul>

Analyst Color

Health Care

Initiation

AVTX

Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside

Investors with significant funds have taken a bearish position in AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in ABBV usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 18 options transactions for AbbVie. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 27% being bullish and 50% bearish. Of all the options we discovered, 17 are puts, valued at $1,635,895, and there was a single call, worth $227,500.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $165.0 and $210.0 for AbbVie, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for AbbVie options trades today is 1585.7 with a total volume of 10,512.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for AbbVie's big money trades within a strike price range of $165.0 to $210.0 over the last 30 days.
<h3>AbbVie 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742917554_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/04/25</td>
<td>$3.6</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$207.50</td>
<td>$734.4K</td>
<td>213</td>
<td>2.4K</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$23.7</td>
<td>$22.75</td>
<td>$22.75</td>
<td>$185.00</td>
<td>$227.5K</td>
<td>1.5K</td>
<td>104</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.5</td>
<td>$4.25</td>
<td>$4.4</td>
<td>$165.00</td>
<td>$220.0K</td>
<td>2.1K</td>
<td>502</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$5.15</td>
<td>$5.05</td>
<td>$5.05</td>
<td>$200.00</td>
<td>$101.0K</td>
<td>1.9K</td>
<td>4</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/11/25</td>
<td>$6.9</td>
<td>$6.9</td>
<td>$6.9</td>
<td>$210.00</td>
<td>$66.2K</td>
<td>4.9K</td>
<td>162</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>AbbVie's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,778,228, with ABBV's price down by -2.24%, positioned at $204.48.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 31 days.</li>
</ul>
<h3>What The Experts Say On AbbVie</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $231.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from B of A Securities persists with their Neutral rating on AbbVie, maintaining a target price of $223. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on AbbVie, which currently sits at a price target of $240. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AbbVie, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Smart Money Is Betting Big In ABBV Options

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has outperformed the market over the past 10 years by 2.91% on an annualized basis producing an average annual return of 13.64%. Currently, AbbVie has a market capitalization of $371.20 billion. 
Buying $1000 In ABBV: If an investor had bought $1000 of ABBV stock 10 years ago, it would be worth $3,610.41 today based on a price of $210.27 for ABBV at the time of writing.
<h3>AbbVie's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742824809_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

<ul>
<li>AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle)</li>
<li>Genmab categorically refutes allegations and will vigorously defend the company</li>
</ul>

GMAB

Reported Friday, Genmab Refutes AbbVie's Trade Secret Allegations Tied to ADC Technology, Vows Vigorous Defense Amid Lawsuit Over ProfoundBio's Rina-S

AbbVie's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) short percent of float has fallen 5.41% since its last report. The company recently reported that it has 18.51 million shares sold short, which is 1.05% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.8 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>AbbVie Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742588124_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AbbVie has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AbbVie's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, AbbVie's peer group average for short interest as a percentage of float is 5.79%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is AbbVie Gaining or Losing Market Support?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$24.00</td>
<td>$50.5K</td>
<td>2.0K</td>
<td>2.0K</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$30.00</td>
<td>$60.2K</td>
<td>2.8K</td>
<td>1.6K</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/28/25</td>
<td>$320.00</td>
<td>$473.7K</td>
<td>609</td>
<td>602</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$320.00</td>
<td>$312.3K</td>
<td>43</td>
<td>502</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$27.50</td>
<td>$35.0K</td>
<td>2.4K</td>
<td>469</td>
</tr>
<tr>
<td>GERN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$1.00</td>
<td>$33.7K</td>
<td>413</td>
<td>397</td>
</tr>
<tr>
<td>EWTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$30.00</td>
<td>$32.2K</td>
<td>5.4K</td>
<td>332</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$230.00</td>
<td>$53.6K</td>
<td>6.9K</td>
<td>295</td>
</tr>
<tr>
<td>CAH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$130.00</td>
<td>$44.2K</td>
<td>2.6K</td>
<td>188</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$57.50</td>
<td>$64.9K</td>
<td>9.5K</td>
<td>167</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option sweep with neutral sentiment. It expires in 56 day(s) on May 16, 2025. Parties traded 200 contract(s) at a $24.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $50.5K, with a price of $253.0 per contract. There were 2012 open contracts at this strike prior to today, and today 2073 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a put option trade that happens to be bearish, is expiring today. Parties traded 300 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $60.2K, with a price of $201.0 per contract. There were 2865 open contracts at this strike prior to today, and today 1625 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bullish sentiment. It expires in 7 day(s) on March 28, 2025. Parties traded 600 contract(s) at a $320.00 strike. This particular put needed to be split into 57 different trades to become filled. The total cost received by the writing party (or parties) was $473.7K, with a price of $779.0 per contract. There were 609 open contracts at this strike prior to today, and today 602 contract(s) were bought and sold. 
• Regarding HCA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), we observe a put option sweep with bearish sentiment. It expires in 27 day(s) on April 17, 2025. Parties traded 474 contract(s) at a $320.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $312.3K, with a price of $660.0 per contract. There were 43 open contracts at this strike prior to today, and today 502 contract(s) were bought and sold. 
• For AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we notice a call option trade that happens to be bearish, is expiring today. Parties traded 20 contract(s) at a $27.50 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $1750.0 per contract. There were 2499 open contracts at this strike prior to today, and today 469 contract(s) were bought and sold. 
• Regarding GERN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>), we observe a call option trade with bearish sentiment. It expires in 210 day(s) on October 17, 2025. Parties traded 397 contract(s) at a $1.00 strike. The total cost received by the writing party (or parties) was $33.7K, with a price of $85.0 per contract. There were 413 open contracts at this strike prior to today, and today 397 contract(s) were bought and sold. 
• Regarding EWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>), we observe a call option sweep with bullish sentiment. It expires in 27 day(s) on April 17, 2025. Parties traded 104 contract(s) at a $30.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $32.2K, with a price of $310.0 per contract. There were 5479 open contracts at this strike prior to today, and today 332 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option sweep that happens to be bearish, expiring in 91 day(s) on June 20, 2025. This event was a transfer of 198 contract(s) at a $230.00 strike. This particular call needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $53.6K, with a price of $271.0 per contract. There were 6965 open contracts at this strike prior to today, and today 295 contract(s) were bought and sold. 
• For CAH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), we notice a call option sweep that happens to be bullish, is expiring today. Parties traded 137 contract(s) at a $130.00 strike. This particular call needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $44.2K, with a price of $325.0 per contract. There were 2600 open contracts at this strike prior to today, and today 188 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option sweep with bearish sentiment. It expires in 91 day(s) on June 20, 2025. Parties traded 116 contract(s) at a $57.50 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $64.9K, with a price of $560.0 per contract. There were 9548 open contracts at this strike prior to today, and today 167 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKRO

AMGN

EWTX

GERN

VKTX

10 Health Care Stocks Whale Activity In Today's Session

Investors with a lot of money to spend have taken a bullish stance on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABBV, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 20 uncommon options trades for AbbVie.
This isn't normal.
The overall sentiment of these big-money traders is split between 70% bullish and 15%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $526,691, and 14 are calls, for a total amount of $1,388,300.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $100.0 to $240.0 for AbbVie over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for AbbVie's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across AbbVie's significant trades, within a strike price range of $100.0 to $240.0, over the past month.
<h3>AbbVie Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742500845_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$41.75</td>
<td>$41.4</td>
<td>$41.75</td>
<td>$170.00</td>
<td>$208.7K</td>
<td>658</td>
<td align="right">101</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$42.5</td>
<td>$42.05</td>
<td>$42.5</td>
<td>$170.00</td>
<td>$195.5K</td>
<td>658</td>
<td align="right">50</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$7.25</td>
<td>$7.2</td>
<td>$7.2</td>
<td>$210.00</td>
<td>$190.1K</td>
<td>1.3K</td>
<td align="right">318</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$50.9</td>
<td>$49.2</td>
<td>$49.75</td>
<td>$165.00</td>
<td>$159.2K</td>
<td>143</td>
<td align="right">57</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$47.5</td>
<td>$46.95</td>
<td>$47.5</td>
<td>$165.00</td>
<td>$152.0K</td>
<td>278</td>
<td align="right">32</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
In light of the recent options history for AbbVie, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is AbbVie Standing Right Now?</h3>
<ul>
<li>With a volume of 3,194,073, the price of ABBV is down -0.36% at $211.49. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 36 days.</li>
</ul>
<h3>What Analysts Are Saying About AbbVie</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $231.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on AbbVie, which currently sits at a price target of $240. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Neutral rating on AbbVie with a target price of $223. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AbbVie, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

AbbVie Options Trading: A Deep Dive into Market Sentiment

Live On CNBC, Josh Brown Hosts Segment Titled "AbbVie Is Breaking Out"

AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) released on Saturday the final analysis of the confirmatory Phase 3 MIRASOL trial of Elahere (mirvetuximab soravtansine-gynx) in women with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">compared to chemotherapy</a>.
The U.S. Food and Drug Administration granted full approval to Elahere <a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/n37898296/u-s-food-and-drug-administration-fda-grants-full-approval-for-elahere-mirvetuximab-soravtansine-gy" rel="noreferrer noopener">in March 2024,</a> and the European Commission approved the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42029072/abbvie-receives-european-commission-approval-of-elahere-mirvetuximab-soravtansine-for-the-treatmen" rel="noreferrer noopener">drug in November 2024</a>.
At 30.5 months median follow-up, treatment with Elahere continued to show significant improvements in progression-free survival (PFS) and overall survival (OS) compared to investigator&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44345849/elahere-mirvetuximab-soravtansine-gynx-shows-consistent-survival-benefit-in-long-term-analysis-for" rel="noreferrer noopener">choice (IC) chemotherapy</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44089215/abbvie-becomes-another-big-pharma-to-enter-obesity-treatment-race" rel="noreferrer noopener">AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race</a>
The Phase 3 MIRASOL study included 453 patients with high-grade serous epithelial PROC whose tumors express high levels of FRα and had been treated with up to three prior therapies:
<ul>
<li>Elahere treatment achieved superior efficacy versus IC chemotherapy, with a median PFS of 5.59 months versus 3.98 months, representing a 37% reduction in the risk of tumor progression or death and a higher objective response rate of 41.9% versus 15.9%.</li>
<li>Superior and clinically meaningful overall survival for patients receiving Elahere (median 16.85 months) compared to IC chemotherapy (median 13.34 months), representing a 32% reduction in the risk of death.</li>
<li>Other endpoints included safety and duration of response (DOR), which were consistent with the primary data analysis at 13.1-months median follow-up.</li>
</ul>
ABBV Price Action: AbbVie stock is up 1.63% at $212.23 at publication Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44358047/pepsico-bets-big-on-prebiotic-sodas-with-1-95-billion-poppi-acquisition-details" target="_blank" rel="noreferrer noopener">PepsiCo Bets Big On Prebiotic Sodas With $1.95 Billion Poppi Acquisition: Details</a></li>
</ul>
Photo: Shutterstock

Large Cap

AbbVie's Elahere Cuts Death Risk By 32%, Shows Consistent Survival Benefit In Long-Term Analysis For Certain Ovarian Cancer Patients

<ul>
<li>Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC)
<ul>
<li>Data presented in a late-breaking oral presentation at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer in Seattle</li>
</ul>
</li>
</ul>

Reported Saturday, AbbVie Highlights Final MIRASOL Results At SGO 2025 Showing Clinically Meaningful Survival Gains With ELAHERE In Platinum-Resistant Ovarian Cancer

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$35.00</td>
<td>$43.0K</td>
<td>680</td>
<td>1.7K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/14/25</td>
<td>$815.00</td>
<td>$26.5K</td>
<td>38</td>
<td>268</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$62.50</td>
<td>$125.9K</td>
<td>90</td>
<td>253</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$360.00</td>
<td>$119.2K</td>
<td>472</td>
<td>203</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/11/25</td>
<td>$210.00</td>
<td>$95.5K</td>
<td>290</td>
<td>193</td>
</tr>
<tr>
<td>IQV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$180.00</td>
<td>$200.2K</td>
<td>31</td>
<td>111</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$490.00</td>
<td>$99.7K</td>
<td>92</td>
<td>77</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$165.00</td>
<td>$26.6K</td>
<td>6.1K</td>
<td>56</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$330.00</td>
<td>$80.8K</td>
<td>14</td>
<td>29</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$600.00</td>
<td>$101.9K</td>
<td>0</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be bullish, expiring in 37 day(s) on April 17, 2025. This event was a transfer of 426 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $43.0K, with a price of $101.0 per contract. There were 680 open contracts at this strike prior to today, and today 1750 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be neutral, expiring in 3 day(s) on March 14, 2025. This event was a transfer of 20 contract(s) at a $815.00 strike. The total cost received by the writing party (or parties) was $26.5K, with a price of $1325.0 per contract. There were 38 open contracts at this strike prior to today, and today 268 contract(s) were bought and sold. 
• For BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we notice a put option sweep that happens to be bearish, expiring in 192 day(s) on September 19, 2025. This event was a transfer of 221 contract(s) at a $62.50 strike. This particular put needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $125.9K, with a price of $570.0 per contract. There were 90 open contracts at this strike prior to today, and today 253 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option trade that happens to be bearish, expiring in 10 day(s) on March 21, 2025. This event was a transfer of 200 contract(s) at a $360.00 strike. The total cost received by the writing party (or parties) was $119.2K, with a price of $596.0 per contract. There were 472 open contracts at this strike prior to today, and today 203 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a put option sweep that happens to be bullish, expiring in 31 day(s) on April 11, 2025. This event was a transfer of 193 contract(s) at a $210.00 strike. This particular put needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $95.5K, with a price of $495.0 per contract. There were 290 open contracts at this strike prior to today, and today 193 contract(s) were bought and sold. 
• Regarding IQV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>), we observe a put option sweep with bullish sentiment. It expires in 283 day(s) on December 19, 2025. Parties traded 110 contract(s) at a $180.00 strike. This particular put needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $200.2K, with a price of $1820.0 per contract. There were 31 open contracts at this strike prior to today, and today 111 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be bullish, expiring in 192 day(s) on September 19, 2025. This event was a transfer of 23 contract(s) at a $490.00 strike. The total cost received by the writing party (or parties) was $99.7K, with a price of $4335.0 per contract. There were 92 open contracts at this strike prior to today, and today 77 contract(s) were bought and sold. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a call option trade with bullish sentiment. It expires in 101 day(s) on June 20, 2025. Parties traded 35 contract(s) at a $165.00 strike. The total cost received by the writing party (or parties) was $26.6K, with a price of $760.0 per contract. There were 6139 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a put option trade that happens to be bullish, expiring in 192 day(s) on September 19, 2025. This event was a transfer of 26 contract(s) at a $330.00 strike. The total cost received by the writing party (or parties) was $80.8K, with a price of $3110.0 per contract. There were 14 open contracts at this strike prior to today, and today 29 contract(s) were bought and sold. 
• Regarding TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we observe a put option trade with neutral sentiment. It expires in 464 day(s) on June 18, 2026. Parties traded 10 contract(s) at a $600.00 strike. The total cost received by the writing party (or parties) was $101.9K, with a price of $10193.0 per contract. There were 0 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Whales with a lot of money to spend have taken a noticeably bullish stance on AbbVie.
Looking at options history for AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) we detected 29 trades.
If we consider the specifics of each trade, it is accurate to state that 51% of the investors opened trades with bullish expectations and 41% with bearish.
From the overall spotted trades, 11 are puts, for a total amount of $663,216 and 18, calls, for a total amount of $842,315.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $120.0 and $230.0 for AbbVie, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for AbbVie's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale trades within a strike price range from $120.0 to $230.0 in the last 30 days. 
<h3>AbbVie Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741379447_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$14.7</td>
<td>$13.65</td>
<td>$14.7</td>
<td>$230.00</td>
<td>$132.3K</td>
<td>42</td>
<td align="right">90</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.68</td>
<td>$1.67</td>
<td>$1.67</td>
<td>$180.00</td>
<td>$131.0K</td>
<td>1.9K</td>
<td align="right">787</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$17.3</td>
<td>$17.1</td>
<td>$17.1</td>
<td>$200.00</td>
<td>$100.8K</td>
<td>1.5K</td>
<td align="right">82</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$4.9</td>
<td>$4.85</td>
<td>$4.9</td>
<td>$210.00</td>
<td>$90.1K</td>
<td>1.4K</td>
<td align="right">588</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$44.0</td>
<td>$43.45</td>
<td>$44.0</td>
<td>$170.00</td>
<td>$88.0K</td>
<td>714</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
After a thorough review of the options trading surrounding AbbVie, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is AbbVie Standing Right Now?</h3>
<ul>
<li>With a trading volume of 4,371,420, the price of ABBV is up by 1.64%, reaching $214.2.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 49 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for AbbVie</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $231.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Neutral rating on AbbVie with a target price of $223. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for AbbVie, targeting a price of $240. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Press Releases

AbbVie to Present at the TD Cowen's 45th Annual Health Care Conference

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis

AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity

AbbVie to Present at the Leerink Partners Global Healthcare Conference

SKYRIZI® (risankizumab) Now Available for Moderately to Severely Active Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease

ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients

Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025

AbbVie to Host First-Quarter 2025 Earnings Conference Call

AVIR

CARM

COYA

MEIP

RIBT

SYBX

TSX:PHO

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Comments

AbbVie

Noticias

Últimas noticias sobre AbbVie (NYSE:ABBV) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL